Teva to launch generic Baraclude

The U.S. Court of Appeals for the Federal Circuit upholds a district court ruling invalidating Bristol-Myers Squibb's (BMY -0.2%) patent no. 5,206,244 for Baraclude (entecavir).

Teva's (TEVA -0.3%) ANDA for a generic version has received tentative approval by the FDA. The commercial launch will commence after the agency issues its final approval.

According to IMS Health, Baraclude's U.S. sales were ~$314M in the 12-month period ending in March.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs